UroGen Pharma Ltd. Ordinary Shares (URGN)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 291
- Market Cap
- $2.4B
About UroGen Pharma Ltd. Ordinary Shares
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
SentiSense also tracks daily options readings for UroGen Pharma Ltd. Ordinary Shares: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
UroGen Pharma Ltd. Ordinary Shares stock analysis, sentiment tracking, and market intelligence on SentiSense.